MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity

Table 4 Dichotomized distribution of MPO and IL-17 according to defined cut-offs (22 cells/punch for MPO and 1 cell/punch for IL-17 [27] in recurrent carcinomas (n = 45)^a

	MPO-/IL17- n = 23 (100 %)	MPO+/IL17- n = 4 (100 %)	MPO-/IL17+ n = 12 (100 %)	MPO+/IL17+ n = 6 (100 %)	p-value
Age (median, range)	62 (47–77)	59.5 (45–69)	59 (34–68)	54.5 (39–60)	0.277
FIGO stage
II	0	0	1 (8.3)	0	0.574
IIIA	0	0	1 (8.3)	0
IIIB	2 (8.7)	0	2 (16.7)	1 (16.7)
IIIC	17 (73.9)	4 (100.0)	6 (50.0)	3 (50.0)
IV	4 (17.4)	0	2 (16.7)	2 (33.3)
Residual disease
None	7 (30.4)	0	6 (50.0)	2 (33.3)	0.046
<2 cm	5 (21.7)	3 (66.7)	5 (41.7)	4 (66.7)
>2 cm	10 (43.5)	1 (33.3)	1 (8.3)	0
Numbers of chemotherapy cycles
<6	3 (13.0)	0	3 (25.0)	1 (16.7)	0.806
6 or more	19 (82.6)	4 (100.0)	9 (75.0)	5 (83.3)	0.806
CS^b	13 (56.5)	3 (66.7)	10 (83.3)	6 (100.0)	0.123
CR^b	10 (43.5)	1 (33.3)	2 (16.7)	0	0.123
RFS^c (mean/SE)	7.7 (1.8)	12.5 (7.1)	14.2 (2.5)	8.3 (2.2)	0.121
OS^c (mean/SE)	33.5 (5.8)	20 (2.0)	53.4 (9.3)	45.2 (6.5)	0.074

Bold data statistically significant p < 0.05
^apercentages may not add to 100 % due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random. Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kruskal-Wallis test. FIGO stage, residual disease, numbers of chemotherapy cycles and chemoresistance were analyzed using the Fisher’s Exact test
^bCS chemosensitive, CR chemoresistant
^cRFS recurrence-free survival, OS overall survival

ISSN: 1471-2407